Article info
PDFExtended essay
COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities
- Correspondence to Dr Euzebiusz Jamrozik, University of Oxford Wellcome Centre for Ethics and Humanities, Oxford, OX3 7LF, UK; euzebiusz.jamrozik{at}ethox.ox.ac.uk
Citation
COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities
Publication history
- Received May 31, 2022
- Accepted September 23, 2022
- First published December 5, 2022.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Other content recommended for you
- University-age vaccine mandates: reply to Lam and Nichols
- Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study
- Ethics of college vaccine mandates, using reasonable comparisons
- Covid-19 vaccination in pregnancy
- The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good
- Pregnancy, fetal, and neonatal outcomes after a first booster dose of covid-19 vaccine during pregnancy in Ontario, Canada: population based, retrospective cohort study
- Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study
- Vaccination and multiple sclerosis in the era of the COVID-19 pandemic
- SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry
- Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study